When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast growth factor 21 analog, designed to treat patients with biopsy-confirmed ...

A dietary supplement used to build muscle – or prevent muscle loss as a result of ageing or illness – is to be trialled as a potential treatment for chronic liver disease.

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...